Finanzen von Krystal Biotech Inc (KRYS)KRYSKrystal Biotech Inc

Evaluating the bottom line, Krystal Biotech, Inc. maintains a gross margin of 94.60%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 49.00%, while the net margin is 45.94%. These profitability ratios, combined with a Return on Equity (ROE) of 20.12%, provide a clear picture of how effectively KRYS converts its operational activities into shareholder value.

In the context of the broader market, KRYS competes directly with industry leaders such as TWST and PCVX. With a market capitalization of $9.77B, it holds a significant position in the sector. When comparing efficiency, KRYS's gross margin of 94.60% stands against TWST's 52.76% and PCVX's N/A. Such benchmarking helps identify whether Krystal Biotech, Inc. is trading at a premium or discount relative to its financial performance.

Krystal Biotech has shown strong revenue growth, with Q2 2026 revenue at $119.22 million and a gross margin of 94.60%. The net income for Q2 2026 was $54.77 million, reflecting a healthy profitability level.